I agree that there are some concerns in some of the numbers, but I am also happy to accept the explanation from the mgmt team. If my memory is correct, CSL expenses R&D and with the cost of some of the Phase 3 trials being paid now, I can understand some of the margin pressure. BUT - watching that it does not "become a habit" will be important.
HT1
News: CSL UPDATE 1-CSL's half-year profit beats estimates on robust blood plasma collections, page-11
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$282.27 |
Change
1.520(0.54%) |
Mkt cap ! $135.9B | |||
| Open | High | Low | Value | Volume |
| $283.65 | $283.70 | $281.46 | $11.47M | 40.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 52 | $282.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $282.27 | 23 | 4 |
View Market Depth
| Last trade - 10.22am 27/12/2024 (20 minute delay) ? |
| CSL (ASX) Chart |
